The inclusion of Janssen Biotech Inc.’s Stelara (ustekinumab) and Novo Nordisk A/S’s NovoLog (insulin aspart) in the initial Medicare price negotiation list surprised some observers. Many thought biosimilar competition on the horizon may disqualify them.
A little-known Inflation Reduction Act provision appears to have negated the move, along with the competing biosimilars’ development timelines
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?